EI
ACRS icon

Ellevest Inc’s Aclaris Therapeutics ACRS Stock Holding History

Ellevest Inc’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-135
Closed – – 1175
2020
Q3 		$0 Hold
135
– – ﹤0.01% 1116
2020
Q2 		$0 Hold
135
– – ﹤0.01% 1103
2020
Q1 		$0 Sell
135
-183
-58% -$249 ﹤0.01% 1065
2019
Q4 		$1K Buy
+318
New +$527 ﹤0.01% 718

Other funds holding ACRS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ellevest Inc's ACRS Position: Q4 2020 in Review

Ellevest Inc sold out of Aclaris Therapeutics (ACRS) in Q4 2020, closing a stake of 135 shares.

Ellevest Inc first reported a position in ACRS in Q4 2019 and held it in 4 quarters. The position peaked at $1K in Q4 2019. 82 funds tracked by Wall St. Rank hold ACRS as of Q4 2020.

  • Ellevest Inc reported no remaining Aclaris Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Ellevest Inc sold 135 Aclaris Therapeutics shares in Q4 2020.
  • Ellevest Inc first reported a position in Aclaris Therapeutics in Q4 2019 and held it in 4 quarters.
  • Ellevest Inc's Aclaris Therapeutics position peaked at $1K in Q4 2019.
  • 82 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2020.

Based on Ellevest Inc's 13F filing for Q4 2020, filed 4 Feb 2021.